Clinical Trial Update: Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial comparing injectable cabotegravir to TDF/FTC for HIV pre-exposure prophylaxis in HIV-uninfected men and transgender women who have sex …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• APRETUDE (CABOTEGRAVIR)
• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-11-24